Epizyme (EPZM) Announces Updated Data from Phase 2 Trial of Tazemetostat in Patients with Relapsed or Refractory FL
Tweet Send to a Friend
Epizyme, Inc. (Nasdaq: EPZM), a late-stage biopharmaceutical company developing novel epigenetic therapies, today reported positive interim data from an ongoing ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
